Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 4/20 | 0.82 |
| ▸ | DGKA | P23743 | 1/20 | 0.76 |
| ▸ | LPAR1 | Q92633 | 7/20 | 0.71 |
| ▸ | LPAR4 | Q99677 | 3/20 | 0.71 |
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 0.71 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.71 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.71 |
| ▸ | LPAR5 | Q9H1C0 | 2/20 | 0.71 |
| ▸ | CES2 | O00748 | 1/20 | 0.71 |
| ▸ | LPAR6 | P43657 | 1/20 | 0.71 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.71 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.63 |
| ▸ | MGLL | Q99685 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | THRB | P10828 | 1/20 | 0.61 |
| ▸ | CNR1 | P21554 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19564920 | 0.98 | FAAH (0.80) | FAAHDGKALPAR1LPAR4LPAR2 | |
| SCHEMBL19564918 | 0.98 | FAAH (0.80) | FAAHDGKALPAR1LPAR4LPAR2 | |
| SCHEMBL19570300 | 0.98 | FAAH (0.80) | FAAHDGKALPAR1LPAR4LPAR2 | |
| SCHEMBL25359256 | 0.98 | FAAH (0.80) | FAAHDGKALPAR1LPAR4LPAR2 | |
| SCHEMBL2732836 | 0.98 | FAAH (0.80) | FAAHDGKALPAR1LPAR4LPAR2 | |
| SCHEMBL24625047 | 0.98 | FAAH (0.80) | FAAHDGKALPAR1LPAR4LPAR2 | |
| SCHEMBL19564924 | 0.98 | FAAH (0.80) | FAAHDGKALPAR1LPAR4LPAR2 | |
| SCHEMBL21436112 | 0.98 | FAAH (0.80) | FAAHDGKALPAR1LPAR4LPAR2 | |
| SCHEMBL21436111 | 0.98 | FAAH (0.80) | FAAHDGKALPAR1LPAR4LPAR2 | |
| SCHEMBL30902502 | 0.98 | FAAH (0.80) | FAAHDGKALPAR1LPAR4LPAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142775-A1 | TREATMENT OF NEURODEGENERATIVE CONDITIONS | BTG INTERNATIONAL LIMITED (GB) | 2012-06-07 | — | — | US | disclosed |
| US-7964641-B2 | administering lipid glycerides for treating neurodegenerative disease such as multiple sclerosis; increasing transforming growth factors and tumor necrosis factors | BTG INTERNATIONAL LIMITED (GB) | 2011-06-21 | — | — | US | disclosed |
| EP-2324828-A1 | Treatment for neurodegenerative conditions | BTG International Limited (GB) | 2011-05-25 | — | — | EP | disclosed |
| US-20100113595-A1 | Treatment of neurodegenerative conditions | BTG INTERNATIONAL LIMITED (GB) | 2010-05-06 | — | — | US | disclosed |
| US-20100113810-A1 | Treatment of neurodegenerative conditions | BTG INTERNATIONAL LIMITED (GB) | 2010-05-06 | — | — | US | disclosed |
| US-20080194684-A1 | Treatment of Neurodegenerative Conditions | BTG INTERNATIONAL LIMITED (GB) | 2008-08-14 | — | — | US | disclosed |
| EP-1660071-A1 | TREATMENT OF NEURODEGENERATIVE CONDITIONS | BTG INTERNATIONAL LIMITED (GB) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005018632-A1 | TREATMENT OF NEURODEGENERATIVE CONDITIONS | BTG INTERNATIONAL LIMITED (GB) | 2005-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194684-A1 | Treatment of Neurodegenerative Conditions | LPAR2, DGAT2, DGKG | FAAH 58/4885DGKA 13/4885LPAR1 36/4885 |
| US-20100113595-A1 | Treatment of neurodegenerative conditions | DGAT2, ALOX12, DGKG | FAAH 56/4885DGKA 13/4885LPAR1 27/4885 |
| US-20120142775-A1 | TREATMENT OF NEURODEGENERATIVE CONDITIONS | DGAT2, ALOX12, DGKG | FAAH 56/4885DGKA 13/4885LPAR1 27/4885 |
| US-20100113810-A1 | Treatment of neurodegenerative conditions | DGAT2, ALOX12, DGKG | FAAH 56/4885DGKA 13/4885LPAR1 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.